Baseline histologic activity predicted colectomy risk in ulcerative colitis treated with biologics, independent of clinical or endoscopic factors.

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Turkey tail: can it really support cancer treatment? - This functional mushroom has experts buzzing for its potential effects ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...

Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $20.4 million, has announced its corporate milestones for 2025, focusing on the development of treatments for ...

A recent study published in the journal Medicine has found a possible connection between low vitamin D levels and increased ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

For people who study the opioid epidemic, 2025 marks a grim anniversary: It has been 30 years since the Food and Drug Administration approved the opioid OxyContin for the treatment of chronic pain.

Multidisciplinary care is needed to ensure positive maternal and fetal health outcomes, especially in complex or high-risk ...

Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...

Patients with CeD also had a higher risk for pernicious anemia (OR = 11.28; 95% CI, 7.33-18.41), Crohn’s disease (OR = 4.18; 95% CI, 3.44-5.13), ulcerative colitis (OR = 3.27; 95% CI ...